Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

European Journal of Cancer

Volumn 48, Issue 1, 2012, Pages 85-93

  Fizazi, K ^a   De Bono, J S ^b   Flechon, A ^c   Heidenreich, A ^d   Voog, E ^e   Davis, N B ^f   Qi, Ming ^g   Bandekar, R ^g   Vermeulen, J T ^g   Cornfeld, M ^g   Hudes, G R ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c CENTRE LÉON BÉRARD   (France)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e Clinique Victor Hugo   (France)

^f FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

^g Ortho Biotech Oncology Research and Development   (United States)

^h FOX CHASE CANCER CENTER   (United States)

Author keywords

CNTO 328 monoclonal antibody; Interleukin 6; Mitoxantrone; Prednisone; Prostatic neoplasms; Safety; Siltuximab; Treatment efficacy

Indexed keywords

C REACTIVE PROTEIN; DOCETAXEL; INTERLEUKIN 6 ANTIBODY; MITOXANTRONE; PREDNISONE; SILTUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; BONE PAIN; BRAIN HEMORRHAGE; CASTRATION RESISTANT PROSTATE CANCER; DETERIORATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HEART FAILURE; HUMAN; HYPOTENSION; INFECTION RATE; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SPINAL CORD COMPRESSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM METASTASIS; ORCHIECTOMY; PREDNISONE; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 83255176682     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.10.014     Document Type: Article

References (29)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. J. Ferlay, P. Autier, and M. Boniol Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 2007 581 592
3. S. Chowdhury, S. Burbridge, and P.G. Harper Chemotherapy for the treatment of hormone-refractory prostate cancer Int J Clin Pract 61 2007 2064 2070
4. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
5. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
6. D.E. Drachenberg, A.A. Elgamal, R. Rowbotham, M. Peterson, and G.P. Murphy Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer Prostate 41 1999 127 133
7. V. Michalaki, K. Syrigos, P. Charles, and J. Waxman Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer Br J Cancer 90 2004 2312 2316
8. V. Michalaki, K. Syrigos, P. Charles, and J. Waxman Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer Br J Cancer 90 2004 2312 2316
9. D.A. Twillie, M.A. Eisenberger, and M.A. Carducci Interleukin-6: a candidate mediator of human prostate cancer morbidity Urology 45 1995 542 549
10. S.F. Shariat, B. Andrews, and M.W. Kattan Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis Urology 58 2001 1008 1015
11. P.C. Smith, and E.T. Keller Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice Prostate 48 2001 47 53
12. Y.S. Pu, T.C. Hour, and S.E. Chuang Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells Prostate 60 2004 120 129
13. L. Wallner, J. Dai, and J. Escara-Wilke Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice Cancer Res 66 2006 3087 3095
14. J. Karkera, H. Steiner, and W. Li The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study Prostate 71 2011 1455 1465
15. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
16. P.W. Kantoff, S. Halabi, and M. Conaway Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study J Clin Oncol 17 1999 2506 2513
17. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
18. D.S. Ernst, I.F. Tannock, and E.W. Winquist Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain J Clin Oncol 21 2003 3335 3342
19. J.E. Rosenberg, V.K. Weinberg, and W.K. Kelly Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone Cancer 110 2007 556 563
20. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
21. C.N. Sternberg, D.P. Petrylak, and O. Sartor Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial J Clin Oncol 27 2009 5431 5438
22. T. Puchalski, U. Prabhakar, Q. Jiao, B. Berns, and H.M. Davis Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma Clin Cancer Res 16 2010 1652 1661
23. K. Fizazi, P. Beuzeboc, and J. Lumbroso Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer J Clin Oncol 27 2009 2429 2435
24. V. Ramiah, D.J. George, and A.J. Armstrong Clinical endpoints for drug development in prostate cancer Curr Opin Urol 18 2008 303 308
25. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
26. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
27. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
28. de Bono JS, Logothetis C, Fizazi K, et al. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): Results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. Presented at: the 35th Annual Congress of the European Society for Medical Oncology; October 8-12, 2010, Milan, Italy.
29. J.S. de Bono, H.I. Scher, and R.B. Montgomery Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 2008 6302 6309